Cardiology Research Group

Hull York Medical School and the University of Hull’s Cardiology Research Group is led by Professor Andrew Clark and specialises in heart failure, including exercise physiology, palliative and end of life care, and a natural history of heart failure. The group undertakes high quality clinical trials both commercial and principal investigator-led, with Dr Angela Hoye leading on interventional cardiology as part of a strong joint research portfolio. The group's research is carried out on a day patient basis by specialist doctors, nurses and technicians in a safe, relaxed and friendly atmosphere.

Currently there are about 3,000 heart failure admissions in the Trust each year, and a large heart failure programme has acquired data over the past fifteen years on more than 10,000 local patients. The unit hosts an impressive array of research tools including advanced ultrasound equipment (VIVID-E9 system), non-invasive haemodynamic monitoring and neuro-endocrine tests, cardiopulmonary exercise testing, and Dexa scanner.


Study to evaluate the effect of Dapagliflozin on the incidence of worsening heart failure of cardiovascular death in patients with reduced ejection fraction 

Funded by: Astra Zeneca UK Ltd


Heart OMics in AGEing - HOMAGE 

As more people survive into old age, the prevalence of heart failure (HF), one of the most common and debilitating diseases in older people, will rise still further. Delaying or preventing HF will have great benefit to those at personal risk, their families, society and the economy. HOMAGE aims to provide a biomarker (BM) approach that will help identify
i. patients at high risk of developing HF before the onset of symptoms and
ii. subsets of patients who are more likely to respond to specifically targeted therapies (personalised medicine).

In available cohorts, we will identify the most promising ‘omics-based BM profiles for the pre-symptomatic diagnosis and future prediction of HF in patients at risk. The predictive value of the BMs for other co-morbidities commonly associated with HF and ageing will also be investigated. Furthermore, in a prospective trial, we will investigate the potential for targeting preventive therapy at patients with the greatest likelihood of response and the lowest risk of adverse effects. Our selection of innovative ‘omics-based BMs is based on knowledge of biological pathways of the disease, which may facilitate identification of ‘Biotargets’ for future therapies. On the economic side, HOMAGE will act as an economic catalyst for European SMEs in the field of cardiovascular and ageing BMs, estimated to peak annual turnovers of up to 800 M€.

Funded by: European Union FP7-HEALTH-2012-INNOVATION-1 - 305507

Hearthub Platform Novartis AG

To provide data from our “Lifelab” Database.

Funded by: IMS Health


International study of comparative health effectiveness with medical and invasive approaches (ISCHEMIA Trial)

Funded by: New York University School of Medicine


GALACTIC: A double-blind, randomized, placebo-controlled, multicentre study to assess the efficacy and safety of Omecamtiv Mecarbil in subjects with chronic heart failure with reduced ejection fraction

Funded by: Amgen Inc


Intravenous iron treatment in patients with heart failure and iron deficiency (IRONMAN)

Funded by: Greater Glasgow Health board


VICTORIA: VerlCigual T GIObal Study in subjects with heart failure with reduced ejection fraction

Funded by: Merck Sharp & Dhome Ltd


PARAGON - A multicentre, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients (NYHA Class II-IV) with preserved ejection fraction

Funded by: Novartis Consumer Health SA